Nelivaptan

Chemical compound From Wikipedia, the free encyclopedia

Nelivaptan (INNTooltip International Nonproprietary Name;[4] developmental code names SSR-149415, NB-415, and BH-200) is a selective, orally active, non-peptide vasopressin V1B receptor antagonist.[1][2][3][5] The drug had entered clinical trials for treatment of anxiety and depression.[1][6] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.[1][7] Subsequently, nelivaptan was developed by Nelivabon for treatment of depressive disorders under the code name NB-145, but development was discontinued in 2022.[2][8][9] However, it is also under development by HMNC Brain Health for major depressive disorder under the code name BH-200, and is in phase 2 trials for this indication as of August 2025.[3]

Other namesSSR-149415; SSR-149,415; SSR149415; NB-415; NB415; BH-200; BH200
Routes of
administrationOral[1][2][3]
Drug classVasopressin V1B receptor antagonist
ATC code
  • None
Quick facts Clinical data, Other names ...
Nelivaptan
Clinical data
Other namesSSR-149415; SSR-149,415; SSR149415; NB-415; NB415; BH-200; BH200
Routes of
administration		Oral[1][2][3]
Drug classVasopressin V1B receptor antagonist
ATC code
  • None
Identifiers
  • (2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidine-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.987 Edit this at Wikidata
Chemical and physical data
FormulaC30H32ClN3O8S
Molar mass630.11 g·mol−1
  • InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1 checkY
  • Key:NJXZWIIMWNEOGJ-WEWKHQNJSA-N checkY
 X markNcheckY (what is this?)  (verify)
Close

See also

References

External links

Related Articles

Wikiwand AI